Recursion Pharmaceuticals (RXRX) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$0.36.
- Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) fell 5.88% to -$0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.84, marking a year-over-year decrease of 18.71%. This contributed to the annual value of -$1.69 for FY2024, which is 6.96% down from last year.
- As of Q3 2025, Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.36, which was up 12.20% from -$0.41 recorded in Q2 2025.
- Recursion Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at -$0.28 for Q3 2021, and its period low was -$1.33 during Q1 2021.
- Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.40 (2024), whereas its average is -$0.41.
- In the last 5 years, Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) crashed by 56.47% in 2021 and then surged by 75.19% in 2022.
- Over the past 5 years, Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.39 in 2021, then increased by 23.08% to -$0.30 in 2022, then plummeted by 40.00% to -$0.42 in 2023, then slumped by 35.71% to -$0.57 in 2024, then declined by 5.88% to -$0.36 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.36 for Q3 2025, versus -$0.41 for Q2 2025 and -$0.50 for Q1 2025.